Pharmacotherapy for Prolonged Grief Disorder
Prolonged grief disorder became an official DSM-5-TR diagnosis in 2022, and grief-focused psychotherapy is its established treatment. Whether medication has any legitimate role at all in a condition built to be treated by therapy is a genuinely open question.
C.H. is a 67-year-old woman, a retired elementary school librarian, whose husband of forty-one years died fourteen months ago after a long illness she nursed him through at home. She lives alone now, near one of her two adult children, and has continued attending her weekly book club, though she describes most of her days as organized entirely around avoiding the parts of the house that were "his." She has well-controlled hypothyroidism and no psychiatric history prior to her husband's death.
What brings her in is not ordinary grief, which her physician correctly recognized as something that should have softened well before now — it is a persistent, functionally impairing yearning for him, difficulty accepting the death as real on some days, and a sense that her own life effectively stopped fourteen months ago, meeting criteria for prolonged grief disorder, a diagnosis only formally added to the DSM-5-TR in 2022. The established treatment is grief-focused psychotherapy, specifically complicated grief treatment, which has the strongest evidence base of anything available for this condition. What she is asking about is whether medication could also help, and the honest answer is genuinely unsettled: several trials of standard antidepressants for prolonged grief have found they may ease comorbid depressive symptoms but do not reliably reduce the core grief symptoms — the yearning, the preoccupation — themselves. A more mechanistically distinct line of research has proposed naltrexone, based on the idea that grief-related yearning may share neurobiology with reward-based craving. It is important to be exact about the status of this one: a randomized, placebo-controlled pilot trial has been designed and registered on that rationale, but no efficacy result has been published. There is a hypothesis and a trial in progress, not an early positive signal.
At the intake visit
Complicated grief treatment is where the real evidence sits, and I want that to be the center of her plan regardless of what we decide about medication. Standard antidepressants have a real but limited role here — they can ease comorbid depressive symptoms, which she has some of, but the trial data is fairly consistent that they don't reliably touch the core yearning and preoccupation that define this diagnosis.
That distinction is worth being precise about with her directly, since it changes what she should expect from a medication trial. If we start an SSRI, it should be framed honestly as targeting her mild depressive symptoms specifically, not as a treatment for the grief itself — the naltrexone work is interesting mechanistically, and reward-circuitry involvement in yearning is a genuinely different theory of the disorder — but I want to be careful not to describe it as promising results, because there aren't results yet. There's a rationale and a pilot trial underway, which is not the same thing and is nowhere near ready to offer outside a research setting.
Then the plan should center CGT referral as the primary treatment, hold off on naltrexone entirely given how limited that evidence still is, and only consider an SSRI later if her depressive symptoms grow more prominent on their own — not now, and not framed to her as something expected to shorten her grief.
C.H. referred for complicated grief treatment as her primary intervention, with medication held for now and explicitly reserved for later if depressive symptoms become more prominent on their own.
Left honestly open: whether any medication will ever have a clearly established role in treating the core symptoms of prolonged grief disorder itself, as opposed to symptoms that merely accompany it, is a question this young diagnosis has not yet had time to answer.